retatrutide phase 2 trial obesity nejm 2023 2023年度回顧】 Notable Articles of Day 3: Triple–Hormone-Receptor Agonist for — A Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis Phase 2 Trial of Retatrutide

Follow the reconstitution guide carefully, store properly at 28C after reconstitution, and use our reconstitution calculator to ensure accurate dosing so you're not over-injecting

Using a pen that delivers 1 mg or 2 mg doses when prescribed 0.25 mg or 0.5 mg results in significant overdosing

Pregnant or breastfeeding women there is currently insufficient safety data to support use during pregnancy or lactation

As seen below, two of the peptides have been prohibited by the World Anti-Doping Agency

[DOI] [PMC free article] [PubMed] [Google Scholar] 30.Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF

Researchers believe Retatrutides three-pronged approach may explain its stronger effects on appetite suppression and calorie burning